凝血因子Xa抑制药研究进展  

Advances in coagulation factor Xa inhibitor

作　　者：黄震华[1] 

机构地区：[1]上海交通大学医学院附属第九人民医院心血管病研究室,上海200011

出　　处：《中国新药与临床杂志》2012年第9期505-510,共6页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：凝血因子Xa是内源性凝血系统和外源性凝血系统的交汇点。针对凝血因子Xa的新型抗凝药物具有疗效显著、使用方便、不需实验室监测、出血不良反应少等优点。间接凝血因子Xa抑制药璜达肝素、艾屈肝素、idrabiotaparinux、SR123781和直接凝血因子Xa抑制药利伐沙班、apixaban、betrixaban、edoxaban、eribaxaban、LY517717、YM150、letaxaban、奥米沙班是目前研究较多的药物。Factor Xa is located at the intersection of the intrinsic and extrinsic pathways in the coagulation cascade. The newer anticoagulant drugs targeting factor Xa have the advantage of good efficacy, more convenience, no laboratory monitoring, and less bleeding side effect. Indirect factor Xa inhibitor fondaparinux, idraparinux, idrabiotaparinux, SR123781 and direct factor Xa inhibitor rivaroxaban, apixaban, betrixaban, edoxaban, eribaxaban, LY517717, YM150, letaxaban, otamixaban are the more studied drugs nowadays.

关 键 词：因子Xa 抗凝药 血栓栓塞 静脉血栓形成 

分 类 号：R973.2[医药卫生—药品]